Form 8-K - Current report:
SEC Accession No. 0001558370-24-009490
Filing Date
2024-06-26
Accepted
2024-06-26 09:15:20
Documents
18
Period of Report
2024-06-26
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nrbo-20240626x8k.htm   iXBRL 8-K 46722
2 EX-99.1 nrbo-20240626xex99d1.htm EX-99.1 20190
3 EX-99.2 nrbo-20240626xex99d2.htm EX-99.2 21411
4 GRAPHIC nrbo-20240626x8k001.jpg GRAPHIC 12152
5 GRAPHIC nrbo-20240626xex99d1001.jpg GRAPHIC 12969
6 GRAPHIC nrbo-20240626xex99d2001.jpg GRAPHIC 12969
  Complete submission text file 0001558370-24-009490.txt   292338

Data Files

Seq Description Document Type Size
7 EX-101.SCH nrbo-20240626.xsd EX-101.SCH 3147
8 EX-101.LAB nrbo-20240626_lab.xml EX-101.LAB 15927
9 EX-101.PRE nrbo-20240626_pre.xml EX-101.PRE 10070
21 EXTRACTED XBRL INSTANCE DOCUMENT nrbo-20240626x8k_htm.xml XML 4871
Mailing Address 545 CONCORD AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address 545 CONCORD AVENUE SUITE 210 CAMBRIDGE MA 02138 (857) 702-9600
NeuroBo Pharmaceuticals, Inc. (Filer) CIK: 0001638287 (see all company filings)

EIN.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37809 | Film No.: 241070860
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)